Publications

Filters: Author is Sondel, P M  [Clear All Filters]
1999
Soergel SA, MacEwen EG, Vail DM, Potter DM, Sondel PM, Helfand SC.  1999.  The immunotherapeutic potential of activated canine alveolar macrophages and antitumor monoclonal antibodies in metastatic canine melanoma.. Journal of immunotherapy (Hagerstown, Md. : 1997). 22(5):443-53. Abstract
1996
Helfand SC, Hank JA, Gan J, Sondel PM.  1996.  Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies.. Cellular immunology. 167(1):99-107. Abstract
1995
Helfand SC, Modiano JF, Moore PF, Soergel SA, MacWilliams PS, Dubielzig RD, Hank JA, Gelfand EW, Sondel PM.  1995.  Functional interleukin-2 receptors are expressed on natural killer-like leukemic cells from a dog with cutaneous lymphoma.. Blood. 86(2):636-45. Abstract
1994
Helfand SC, Soergel SA, Donner RL, Gan J, Hank JA, Lindstrom MJ, Sondel PM.  1994.  Potential to involve multiple effector cells with human recombinant interleukin-2 and antiganglioside monoclonal antibodies in a canine malignant melanoma immunotherapy model.. Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy. 16(3):188-97. Abstract
Helfand SC, Soergel SA, Modiano JF, Hank JA, Sondel PM.  1994.  Induction of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose human recombinant interleukin-2 in vitro.. Cancer biotherapy. 9(3):237-44. Abstract
Helfand SC, Soergel SA, MacWilliams PS, Hank JA, Sondel PM.  1994.  Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogs.. Cancer immunology, immunotherapy : CII. 39(2):84-92. Abstract